Kaneka officially starts continuous manufacturing in GMP condition20 Aug 2018
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) installed continuous manufacturing equipment to be applied to small molecule pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko Yamada) and have started commercial production in GMP*1 condition June 2018.
In small molecule pharmaceutical market, trend is moving towards widely varied smaller volumes. In order to address these changes, new efficient production technology is required. Continuous manufacturing, or Flow Chemistry, is a manufacturing technology that achieves spontaneous reaction to charge raw materials step-by-step into reaction tubing and presents an easy, safe and convenient approach to manufacturing, including reactions that may require tough or dangerous conditions under typical batch reaction. This new equipment is a unique, Kaneka designed, reactor that allows diversity of application through the ability to select the relevant parameters of the reaction tubing and provides the highest performance of reactions. Kaneka Singapore has been qualified as a manufacturer from the US FDA*2 in 2017, and we expect to apply such continuous manufacturing infrastructure to various products, including targets requiring GMP
Kaneka has capability from process development to commercial production with excellent quality assurance, and this new technology will enhance our business in small molecule pharmaceutical. With biological pharmaceutical activities, we now aim to expand our business in Health Care field.
Paid-in Capital: 16million Singapore dollars
Business field: Sales and manufacturing of pharmaceutical products.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation